SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

OPSYNVI

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved / marketed (per public record, could not be re-verified via web this session; no approval row in local FDA tab
Time to market
Already on the market (reported); no new approval timeline applies.
Why 3/10
No hard, dated OPSYNVI-specific catalyst (PDUFA, pivotal readout, or label decision) is scheduled in the next ~12 months in any source retrievable this session, and as an already-marketed drug inside a ~$600B mega-cap the defining binary has passed, so the score is capped at the approved/no-pending-decision band and set at 3 because OPSYNVI is a tiny share of JNJ's value.
Actionable Insight NEUTRAL

For a JNJ shareholder, OPSYNVI is not a trade, it has no dated binary in the next 12 months and is a rounding error inside a ~$600B market cap, so any single-product news would barely move the stock. Watch quarterly filings for PAH revenue commentary and the competitive ralinepag/sotatercept readouts for class-level context; investors who want a PAH-specific catalyst should look at smaller single-asset developers instead.

Price Chart

Loading chart...

Executive Summary

OPSYNVI is the brand name for a fixed-dose combination of macitentan (an endothelin receptor antagonist) plus tadalafil (a PDE5 inhibitor), one daily pill combining two established drug classes used to lower blood pressure in the lungs in pulmonary arterial hypertension (PAH). It is marketed by Johnson & Johnson (JNJ), and the filing hint checks out: JNJ is verified as JOHNSON & JOHNSON (NYSE, pharma), and local FDA/trial data confirm macitentan is a J&J/Actelion PAH franchise drug with completed Phase 3 pediatric PAH trials and already-genericized competition. Net investor read: a real but niche product inside a diversified mega-cap with no near-term binary; nothing to trade on by itself.

How It Works

PAH is high blood pressure in the arteries of the lungs, which strains the right side of the heart. OPSYNVI packs two oral medicines into one pill: macitentan, an "endothelin receptor antagonist" that blocks a signaling protein that narrows lung blood vessels, and tadalafil, a "PDE5 inhibitor" that helps the vessel walls relax and widen. Both effects reduce lung blood pressure. Local FDA data this session confirm macitentan's class and use (endothelin receptor antagonist, oral, PAH) and its embryo-fetal toxicity warning; J&J (Janssen/Actelion) sponsors macitentan PAH trials.

Trial Status

No OPSYNVI-specific trial or approval record exists in SecBot's local FDA-action, catalyst, or trial tables. Corroborating evidence: J&J's macitentan franchise is mature, completed Phase 3 pediatric PAH trials (NCT05167825, NCT02932410) and FDA safety-labeling actions for generic macitentan from Apotex, Aurobindo and Zydus, indicating the single-agent ERA is already off patent.

The Two-Sided Case

▲ Bull Case4
Drug classes are validated and corroborated this session: macitentan is an FDA-recognized endothelin receptor antagonist for PAH, and J&J/Janssen has completed Phase 3 macitentan PAH trials in children (NCT05167825, NCT02932410).
Single-pill convenience (two complementary mechanisms in one daily tablet) is a genuine patient-burden improvement vs. taking the agents separately, a low-technical-risk formulation play.
OPSYNVI rides J&J's huge commercial machine: JNJ is a ~$618B market-cap pharma (8-K analysis) with a buy-leaning consensus (22 analysts, mean price target $272.5, ~6.7% implied upside per local analyst snapshot).
J&J's core fundamentals are strong (Q2 2026 adjusted EPS $2.90 beat, raised FY guidance per local 8-K earnings analysis), providing a stable backdrop even if OPSYNVI contributes little.
▼ Bear Case4
No OPSYNVI-specific record appears in any local FDA/catalyst/trial table and no scheduled binary catalyst exists for it in the next ~12 months, there is nothing to trade on.
Competition is real and intensifying: Merck is running Phase 3 sotatercept in PAH and United Therapeutics has a large (687-patient) Phase 3 ralinepag readout pending, and macitentan as a single agent is already genericized (Apotex, Aurobindo, Zydus ANDA safety labelings), pressuring the franchise's pricing.
OPSYNVI was not named among J&J's Q2 2026 growth drivers (DARZALEX, CARVYKTI, TREMFYA, SPRAVATO), underscoring that PAH is immaterial to JNJ earnings, any product-specific surprise moves the stock negligibly.
Recent insider Form 4 sales by the CEO (~$32M gross on 8/13/2026) and CLO (~$4M) are routine, but they add no bullish signal at the company level.

Upcoming Catalysts

  • None scheduled for OPSYNVI in local data, watch J&J quarterly earnings/filings for PAH portfolio commentary.
  • Competitive PAH readouts (e.g., United Therapeutics' ralinepag Phase 3 results) could shift market-share expectations for the whole PAH drug class.
  • J&J Innovative Medicine leadership transition (Taubert retirement, Cavanaugh succession effective Sept 1, 2026) may signal portfolio priorities.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov